-
Research Progress of Glucose Sensitive Insulin Smart Drug Delivery System
PharmaSources/Xiao Ni Sha
December 10, 2021
Diabetes is one of the major social health problems in the world. Subcutaneous injection of insulin is the traditional administration in the diabetes treatment, which is inconvenient and painful.
-
Human trial data of oral small molecule PD-1/PD-L1 inhibitors were first released
PharmaSources/Xiaoyaowan
December 02, 2021
Recently, Incyte of the United States reported the Phase I clinical data of oral small molecule PD-L1 inhibitor INCB086550 in Journal for ImmunoTherapy of Cancer.
-
Closely following Pralsetinib, the second RET inhibitor in China was applied for production
PharmaSources/Yi
December 02, 2021
On November 9, according to the CDE official website, the listing application of Eli Lilly's RET inhibitor "Selpercatinib Capsule" was accepted.
-
New treatment methods are expected to be created for ALS patients. Amylyx submitted NDA of AMX0035 in the United States
PharmaSources/Yi
December 02, 2021
On November 2, Amylyx Pharmaceuticals announced that it had submitted a new drug application of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS) to FDA.
-
Money and Myths Surrounding the COVID-19 Vaccines
PharmaSources/Nik Patel
December 02, 2021
Covid vaccines have demonstrated themselves to be highly effective, reducing the need for hospitalisation and risk of death by a massive 95%.
-
ADC vs PDC-- Status Quo of the R&D of ADC-PDC Drug in China and the World
PharmaSources/zhulikou431
November 15, 2021
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
-
New Results for Several New β-lactamase Inhibitors
PharmaSources/Yi
November 15, 2021
Recently, the application for clinical trial of Class I drug XNW4107 for injection from Suzhou Sinovent Pharmaceuticals Co., Ltd. was accepted.
-
Research and Application of In-situ Gel Preparation
PharmaSources/Sha Luo
November 15, 2021
In-situ gel is a kind of liquid preparation, which will immediately transform to non-chemically crosslinked semisolid gel in the application site after administration. As a new formulation, in-situ gel has become one of...
-
With the help of Multiple Parties, the Pediatric Drugs Market Space has been Expanding
PharmaSources/Yi
November 08, 2021
Recently, cyclophosphamide capsules of Hengrui Medicine and human growth hormone recombination injection of GeneScience Pharmaceuticals were proposed to be included in the priority review by CDE...
-
The production application of first second-generation glycopeptide antibiotics in China has been submitted, and a number of new antibiotics have been approved globally
PharmaSources/Yi
November 01, 2021
On October 12, CDE official website showed that the import application submitted by SciClone Pharmaceuticals for type 5.1 telavancin hydrochloride for injection was accepted.